AI Article Synopsis
- Parecoxib is a unique injectable pain reliever that selectively targets cyclooxygenase-2 (COX-2), and the review aimed to compare its effectiveness and safety against other pain relievers after surgery.
- In a meta-analysis of 9 trials involving over 1,000 patients, parecoxib showed a higher likelihood of being rated as a "good" or "excellent" pain management option, with favorable numbers needed to treat (NNT) for both prophylactic and treatment scenarios.
- Despite its effectiveness, there were no significant differences in adverse effects between parecoxib and other pain medications tested, indicating it may be a safe option, though further research is needed to finalize the best usage practices.
Article Abstract
Parecoxib is the only parenterally administered cyclooxygenase-2-selective inhibitor available. We performed a systematic review, including full reports of randomized comparisons of parecoxib compared with any other analgesic intervention for prophylaxis or treatment of postoperative pain. Dichotomous data on patients' global evaluation of their analgesic regimen were extracted by means of the fraction of patients who rated their medication as "good" or "excellent." For safety analysis, data on any reported adverse effects were extracted. Relative risk (RR), number needed to treat (NNT), or number-needed-to-harm were calculated with 95% confidence intervals (CI). Data from 9 trials of 50 initially screened were finally analyzed. One thousand thirteen patients were randomized to receive parecoxib, 218 patients were allocated to an active control, and 507 patients received a placebo. With prophylactic administration, the pooled NNT to obtain the desired outcome ("good"/"excellent" rating) with parecoxib 20 and 40 mg compared with placebo was 4.5 (RR, 1.42; 95% CI, 0.91-2.24) and 4.0 (RR, 1.40; 95% CI, 1.10-1.79), respectively. In the treatment trials, the NNT to obtain the outcome of interest with parecoxib 20 mg was 2.1 (RR, 3.44; 95% CI, 1.49-7.96), 5.3 (RR, 1.43; 95% CI, 1.01-2.02), and -8.3 (RR, 0.85; 95% CI, 0.75-0.97) for the comparisons with placebo, morphine, and ketorolac, respectively. The corresponding NNT for treatment with parecoxib 40 mg was 1.7 (RR, 4.65; 95% CI, 2.04-10.61), 3.7 (RR, 1.62; 95% CI, 1.21-2.16), and 50 (RR, 1.03; 95% CI, 0.89-1.18) for the comparisons with placebo, morphine, and ketorolac, respectively. Overall adverse effects for parecoxib 20 and 40 mg were not different from those with placebo, morphine, or ketorolac. These results suggest a favorable profile for parecoxib compared with inactive or active controls. The optimal dose, timing, and frequency of administration need to be determined.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1213/01.ANE.0000133139.68208.92 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Transdermal buprenorphine patch as an adjunct to multimodal analgesia after total joint arthroplasty: a retrospective cohort study.
Front Pharmacol
September 2024
Department of Pharmacy, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
Background: Total hip arthroplasty or total knee arthroplasty (THA/TKA) is often associated with varying degrees of pain. In recent years, transdermal buprenorphine (TDB) patch has shown encouraging results for acute postoperative pain control in orthopedic surgery. The aim of our study was to investigate the efficacy and safety of the combination of TDB patch and nonsteroidal anti-inflammatory drugs (NSAIDs) as a multimodal analgesic regimen after THA/TKA.
View Article and Find Full Text PDFIncreased levels of Escherichia-Shigella and Klebsiella in the gut contribute to the responsivity of placebo analgesia.
Neuropharmacology
December 2024
Department of Anesthesiology and Perioperative Medicine, The First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, China. Electronic address:
Article Synopsis
- Placebo analgesia, the phenomenon where individuals experience pain relief from a placebo, involves complex neurobiological, psychological, and psychosocial factors, and its mechanisms need further research.
- A study with mice showed that about 40% of those trained to associate a pain reliever with specific cues exhibited placebo analgesia, and these responders had lower anxiety-like behaviors.
- Analysis of gut microbiota revealed that placebo responders had higher levels of Escherichia-Shigella and Klebsiella compared to non-responders and controls, suggesting a possible connection between gut microbes and the effectiveness of placebo analgesia.
Insights from pharmacovigilance and pharmacodynamics on cardiovascular safety signals of NSAIDs.
Front Pharmacol
September 2024
Key Laboratory of Neurogenetics and Channelopathies of Guangdong Province and the Ministry of Education of China, Guangzhou Medical University, Guangzhou, China.
Background And Aim: Non-steroidal anti-inflammatory drugs (NSAIDs) are commonly used to treat fever, pain, and inflammation. Concerns regarding their cardiovascular safety have been raised. However, the underlying mechanism behind these events remains unknown.
View Article and Find Full Text PDFBackground: Total Knee Arthroplasty (TKA) is a well-established surgical procedure for the treatment of knee joint diseases. This operation leads to severe acute and chronic pain, and intravenous administration of parecoxib could provide significant pain relief.
Objective: The aim of the study was to compare the hemodynamic data and safety profile of patients who received parecoxib compared to placebo following TKA.
Effect of parecoxib on postoperative cognitive function and analgesic safety in elderly patients undergoing gastrointestinal tumor resection: A retrospective study.
Biomol Biomed
September 2024
Department of Anesthesiology, The Fourth People's Hospital of Nanchong, Nanchong, China.
Neuroinflammation is associated with the development of postoperative cognitive dysfunction (POCD). Parecoxib has powerful anti-inflammatory and analgesic effects, which may reduce the occurrence of POCD. We hypothesized that parecoxib could reduce the incidence of POCD and relieve postoperative pain without increasing postoperative complications in elderly patients with gastrointestinal cancer.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!